Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Oncology Letters

Volumn 1, Issue 2, 2010, Pages 253-259

  Aoyagi, Yoshiko ^a   Iinuma, Hisae ^a   Horiuchi, Atsushi ^a   Shimada, Ryu ^a   Watanabe, Toshiaki ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; FOLFOX; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor A

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 77955755832     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000045     Document Type: Article

References (34)

1. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
2. Hurwits H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
3. Iwasaki J and Nihira S: Anti-angiogenic therapy against gastrointestinal tract cancers. Jpn J Clin Oncol 16: 1-9, 2009.
4. Yamaguchi K, Boku N, Kato K, Komatsu Y, Muro K and Hamamoto Y: Preliminary efficacy, safety and operability of bevacizumab plus capecitabine plus oxaliplatin (XELOX) as first-line therapy in Japanese patients with initially unresectable metastatic colorectal cancer. Ann Oncol 19: viii 130, 2008.
5. Karapetis CS, Khambata FS, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
6. Willett CG, Boucher Y, Duda DG, et al: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial and rectal cancer patients. J Clin Oncol 22: 8136-8139, 2005.
7. Galizia G, Lieto E, Ferraraccio F, et al: Determination of molecular marker expression can predict clinical outcome in colon carcinoma. Clin Cancer Res 10: 3490-3499, 2004.
8. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity metastasis and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
9. Werther K, Christensen IJ and Nielsen HJ: Prognostic impact of matched preoperative plasma and serum VEG F in patients with primary colorectal carcinoma: Br J Cancer 86: 417-423, 2002.
10. Broll R, Erdmann H, Duchrow M, et al: Vascular endothelial growth factor (VEG F) - a valuable serum tumor marker in patients with colorectal cancer? Eur J Surg Oncol 27: 37-42, 2001.
11. Willett CG, Boucher Y, Duda DG, et al: Efficacy, safety and biomarkers of neoadjuvant bevacizumab, radiation therapy and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 18: 3020-3026, 2009.
12. Denduluri N, Yang SX, Berman AW, Nguyen D, Liewehr DJ, Steinberg SM and Swalin SM: Circulating biomarkers of bevacizumab activity in patients. Cancer Biol Ther 7: 15-20, 2008.
13. Ferrara N and Alitalo K: Clinical application of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364, 1999.
14. Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Func 26: 25-35, 2001.
15. Kendall RL and Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993.
16. Kendall RL, Wang G and Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328, 1996.
17. Harris AL, Reusch P, Barlenon B, Hang C, Dobbs N and Marme D: Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin cancer Res 7: 1992-1997, 2001.
18. Toi M, Bando H, Ogawa T, Muta M, Horing C and Weich HA: Significance of vascular endothelial growth factor (VEGF)/soluble VEG F receptor-1 relationship in breast cancer. Int J Cancer 98: 14-18, 2002.
19. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V and Topuz E: Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 16: 405-411, 2006.
20. Yamaguchi T, Nando H, Mori T, et al: Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci 98: 405-410, 2007.
21. Hu Q, Dey AL, Yang Y, et al: Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myeloidysplastic syndromes. Cancer 100: 1884-1891, 2004.
22. Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D and Harris AL: A critical review of vascular endothelial growth factor (VEG F) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 19: 651-663, 2002.
23. Otrock ZK, Makarem JA and Shamseddine AI: Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 38: 258-268, 2007.
24. Poon RT, Fan ST and Wong J: Clinical implication of circulating angiogenic factors in cancer patients. J Clin Oncol 19: 1207-1225, 2001.
25. Burstein A, Chen Y-H and Parker LM: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEG F therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14: 7871-7877, 2008.
26. Holden SN, Ryan E, Kearns A, Holmgren E and Hurwitz H: Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEG F) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 123: 3555, 2005.
27. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signaling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
28. Herold MC, Steiner HH, Andl T, et al: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 79: 1573-1582, 1999.
29. Masood R, Cai J, Zheng T, Smith DL, Hinton DR and Gill PS: Vascular endothelial growth factor (VEG F) is an autocrine growth factor for VEG F receptor-positive human tumors. Blood 98: 1904-1913, 2001.
30. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
31. Holash J, Davis S, Papadopoulos N, et al: VEG F-Trap: a VEG F blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398, 2003.
32. Wierzbowska A, Robak T, Wizesien-Kus A, Krawczynska A, Maranda EL and Urbanska-Rys H: Circulating VEGF and its soluble receptors sVEG FR-1 and sVEG FR-2 in patients with acute leukemia. Eur Cytokine Netw 14: 149-153, 2003.
33. AI-Moundhri M, Shukaili A, AI-Nabhani M, AI-Bahrani B, Burney IA, Rozovo A and Ganguly SS: Measurement of circulating levels of VEGF-A, -C and -D and their receptors, VEG FR-1 and -2 in gastric adenocarcinoma. World Gastroenterol 14: 3879-3883, 2008.
34. Ustuner Z, Saip P, Yasasever V, et al: Prognostic and predictive value of vascular endothelial growth factor and its soluble reseptor VEG FR-1 and VEG FR-2 levels in the sera of small cell lung cancer patients. Med Oncol 25: 394-399, 2008.